Bliss GVS Pharma Limited Fundamental Analysis
Bliss GVS Pharma Limited Fundamental Analysis
Bliss GVS Pharma Limited (BLISSGVS.NS) shows weak financial fundamentals with a PE ratio of 38.75, profit margin of 13.93%, and ROE of 11.56%. The company generates $9.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 73.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BLISSGVS.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakBLISSGVS.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateBLISSGVS.NS shows balanced valuation metrics.
Growth Score
ModerateBLISSGVS.NS shows steady but slowing expansion.
Financial Health Score
ExcellentBLISSGVS.NS maintains a strong and stable balance sheet.
Profitability Score
WeakBLISSGVS.NS struggles to sustain strong margins.
Key Financial Metrics
Is BLISSGVS.NS Expensive or Cheap?
P/E Ratio
BLISSGVS.NS trades at 38.75 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BLISSGVS.NS's PEG of 0.76 indicates potential undervaluation.
Price to Book
The market values Bliss GVS Pharma Limited at 4.29 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 21.21 times EBITDA. This signals the market has high growth expectations.
How Well Does BLISSGVS.NS Make Money?
Net Profit Margin
For every $100 in sales, Bliss GVS Pharma Limited keeps $13.93 as profit after all expenses.
Operating Margin
Core operations generate 12.82 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.56 in profit for every $100 of shareholder equity.
ROA
Bliss GVS Pharma Limited generates $8.65 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bliss GVS Pharma Limited generates limited operating cash flow of $754.11M, signaling weaker underlying cash strength.
Free Cash Flow
Bliss GVS Pharma Limited produces free cash flow of $469.71M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $4.44 in free cash annually.
FCF Yield
BLISSGVS.NS converts 0.97% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.75
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.76
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.29
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.36
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How BLISSGVS.NS Stacks Against Its Sector Peers
| Metric | BLISSGVS.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.75 | 33.92 | Worse (Expensive) |
| ROE | 11.56% | 393.00% | Weak |
| Net Margin | 13.93% | -41456.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.80 | Strong (Low Leverage) |
| Current Ratio | 4.02 | 4.57 | Strong Liquidity |
| ROA | 8.65% | -293.00% (disorted) | Weak |
BLISSGVS.NS outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bliss GVS Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation